The efficacy of combining ondansetron with dexamethasone in delayed chemotherapy-induced nausea and vomiting

Authors

  • Ratih Pratiwi Sari Department of Pharmacy. Faculty of Pharmacy, University of Muhammadiyah Banjarmasin, Banjarmasin & Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia https://orcid.org/0009-0000-1650-6469
  • Muhammad Darwin Prenggono Department of Internal Medical Specialist, Medical Faculty, University of Lambung Mangkurat, Banjarmasin & Ulin General Hospital, Banjarmasin, Indonesia
  • Aditya Maulana Perdana Putra Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Lambung Mangkurat, Banjarbaru, Indonesia https://orcid.org/0000-0003-3444-4059
  • Dewi Susanti Atmaja Department of Pharmacy, Faculty of Health, Universitas Sari Mulia, Banjarmasin, Indonesia https://orcid.org/0000-0001-6479-6587
  • Mahardian Rahmadi Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia
  • Suharjono Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

DOI:

https://doi.org/10.46542/pe.2024.243.211215

Keywords:

Antiemetics, Chemotherapy, Dexamethasone, Efficacy, Ondansetron

Abstract

Background: Chemotherapy is the primary recourse for patients with cancer that cannot be treated using local surgery or radiotherapy. Its practical application often leads to adverse effects, including nausea and vomiting.    

Objective: This study determined the efficacy of oral ondansetron and oral dexamethasone as an antiemetic regimen among patients covered by the National Health Insurance.    

Methods: This cross-sectional study, conducted at one of the largest hospitals in South Kalimantan, Indonesia, involved 114 chemotherapy patients who received a combination antiemetic regimen of ondansetron and dexamethasone. Data on the incidence of delayed nausea and vomiting after chemotherapy were collected using the Index Nausea Vomiting and Retching (INVR) questionnaire from March to May 2023.    

Results: A cohort of 114 individuals were enrolled in the present investigation, with 57.02% and 42.98% of the participants receiving non-anthracycline and anthracycline-based treatment protocols, respectively. The results showed that only 1.84% of patients did not experience chemotherapy-related adverse events, 13.16% experienced mild symptoms, 21.84% had moderate symptoms, 55.26% faced severe symptoms, and 7.89% suffered from intense symptoms of nausea and vomiting.    

Conclusion: The antiemetic regimen covered by Badan Penyelenggara Jaminan Sosial (BPJS) (Social Insurance Administration Organization), consisting of a combination of ondansetron and dexamethasone, is moderately effective in preventing chemotherapy-induced delayed nausea and vomiting.

References

Aapro, M., Molassiotis, A., Dicato, M., Peláez, I., Rodríguez-Lescure, Á., Pastorelli, D., & Roila, F. (2012). The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Annals of Oncology, 23(8), 1986‒1992. https://doi.org/10.1093/annonc/mds021

Baburaj, G., Abraham, A. M., George, L., Shetty, V., Thempalangad, R. M., Rajesh, K. S., & Bharath Raj, K. C. (2017). A study on utilization and evaluation of antiemetics in chemotherapy-induced nausea and vomiting. Indian Journal of Medical and Paediatric Oncology, 38(3), 334‒339. https://doi.org/10.4103%2Fijmpo.ijmpo_116_17

Berger, M. J., Ettinger, D. S., Aston, J., Barbour, S., Bergsbaken, J., Bierman, P. J., & Hughes, M. (2017). NCCN guidelines insights: Antiemesis, Version 2.2017. Journal of the National Comprehensive Cancer Network, 15(7), 883‒893. https://doi.org/10.6004/jnccn.2017.0117

Dipiro, C. V., Schwinghammer, T. L., Dipiro, J. T., & Wells, B. G. (2017). Pharmacotherapy handbook, Tenth Edition: McGraw-Hill Education.

Dranitsaris, G., Molassiotis, A., Clemons, M., Roeland, E., Schwartzberg, L., Dielenseger, P., Jordan, K., Young A., & Aapro, M. (2017). The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Annals of Oncology, 28(6), 1260‒1267. https://doi.org/10.1093/annonc/mdx100

Escobar, Y., Cajaraville, G., Virizuela, J. A., Álvarez, R., Muñoz, A., Olariaga, O., & Tornamira, M. V. (2015). Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care in Cancer, 23(9), 2833‒2840. https://doi.org/10.1007%2Fs00520-015-2809-3

Gilmore, J. W., Peacock, N. W., Gu, A., Szabo, S., Rammage, M., Sharpe, J., & Burke, T. A. (2014). Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. Journal of Oncology Practice, 10(1), 68‒74. https://doi.org/10.1200/jop.2012.000816

Grunberg, S. (2012). Patient-centered management of chemotherapy-induced nausea and vomiting. Cancer Control, 19(2), 10‒15. https://doi.org/10.1177/107327481201902s03

Gupta, K., Walton, R., & Kataria, S. P. (2021). Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treatment and Research Communications, 26, 100278. https://doi.org/10.1016/j.ctarc.2020.100278

Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., & Lyman, G. H. (2017). Antiemetics: American society of clinical oncology clinical practice guideline update. Journal of Clinical Oncology, 35(28), 3240‒3261. https://doi.org/10.1200/jco.2017.74.4789

Khairani, S., Keban, S. A., & Afrianty, M. (2019). Evaluation of drug side effects chemotherapy on quality of life (QOL) breast cancer patients at hospital X in Jakarta. Jurnal Ilmu Kefarmasian Indonesia, 17(1), 9‒13. https://doi.org/10.35814/jifi.v17i1.705

Ministry of Health of the Republic of Indonesia. (2019). Hasil utama RISKESDAS 2018. Badan Penelitian dan Pengembangan Kesehatan Kemenkes RI.

Moradian, S., & Howell, D. (2015). Prevention and management of chemotherapy-induced nausea and vomiting. International Journal of Palliative Nursing, 21(5), 216‒224. https://doi.org/10.12968/ijpn.2015.21.5.216

Rhodes, V. A., & McDaniel, R. W. (1999). The index of nausea, vomiting, and retching: A new format of the index of nausea and vomiting. Oncology Nursing Forum, 26(5), 889‒894. PMID: 10382187

Roila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R. J., Bruera, E., & van der Wetering, M. (2016). 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of Oncology, 27(5), v119‒v133. https://doi.org/10.1093/annonc/mdw270

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209‒249. https://doi.org/10.3322/caac.21660

Todd, A., Brierley-Jones, L., Husband, A., Williamson, S., Sarai, I., & Ling, J. (2013). Be clear on cancer: Pharmacy students' views of communicating with cancer patients. Pharmacy Education, 13(0). https://pharmacyeducation.fip.org/pharmacyeducation/article/view/256

Tsubata, Y., Nakao, M., Amano, Y., Hotta, T., Hamaguchi, M., Okimoto, T., & Isobe, T. (2019). Translational and randomized study of 5-HT3 receptor antagonists for evaluation of chemotherapy-induced nausea and vomiting related biomarkers. International Journal of Medical Investigation, 66(3.4), 269‒274. https://doi.org/10.2152/jmi.66.269

Vaid, A. K., Gupta, S., Doval, D. C., Agarwal, S., Nag, S., Patil, P., & Barkate, H. (2020). Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective. Frontiers in Oncology, 10, 400. https://doi.org/10.3389/fonc.2020.00400

Downloads

Published

01-05-2024

How to Cite

Sari, R. P., Prenggono, M. D., Putra, A. M. P., Atmaja, D. S., Rahmadi, M., & Suharjono. (2024). The efficacy of combining ondansetron with dexamethasone in delayed chemotherapy-induced nausea and vomiting. Pharmacy Education, 24(3), p. 211–215. https://doi.org/10.46542/pe.2024.243.211215

Issue

Vol. 24 No. 3 (2024): IGSCPS Special Edition

Section

Special Edition

License

It is a condition of the publication that authors vest or license copyright in their articles, including abstracts, in FIP. This enables us to ensure full copyright protection and to disseminate the article, and the journal, to the widest possible readership in print and electronic formats as appropriate. Authors may, of course, use the material elsewhere after publication providing that prior permission is obtained from FIP. Authors are themselves responsible for obtaining permission to reproduce copyright material from other sources.